Autobahn Therapeutics Reports Promising Phase 2 Results for Elunetirom in Treating Bipolar Depression
Autobahn Therapeutics Reports Positive Phase 2 Topline Data for Elunetirom in Bipolar Depression, Demonstrating Rapid, Robust, and Durable Antidepressant Effects
Businesswire
Image: Businesswire
Autobahn Therapeutics announced positive Phase 2 results for elunetirom, showing a 16.8-point improvement in depression scores and a 75% response rate in patients with bipolar depression. This novel treatment, which received FDA Fast Track designation, demonstrated rapid onset and a favorable safety profile, indicating potential as a new therapy for this condition.
- 01Elunetirom achieved a clinically significant 16.8-point reduction in Hamilton Depression Rating Scale (HAMD-17) scores by Week 6, with rapid improvements observed as early as Week 2.
- 02The trial reported a 75% response rate and a 50% remission rate at Week 6, highlighting its effectiveness.
- 03Elunetirom is a CNS thyroid hormone receptor agonist, designed to enhance brain energy metabolism and neuroplasticity, offering a novel treatment mechanism.
- 04The safety profile was favorable, with no serious treatment-related adverse events reported during the trial.
- 05Elunetirom has received Fast Track designation from the U.S. FDA for treating bipolar depression, facilitating its development and potential market entry.
Advertisement
In-Article Ad
Autobahn Therapeutics, based in San Diego, reported promising topline data from its Phase 2 AMPLIFY-BD trial for elunetirom, an investigational treatment for bipolar I and II depression. The trial demonstrated a 16.8-point improvement in the Hamilton Depression Rating Scale (HAMD-17) total score, achieving statistical significance (p<0.001). Notably, 75% of participants responded to treatment, and 50% achieved remission by Week 6, with rapid effects seen as early as Week 2. Elunetirom, a CNS thyroid hormone receptor agonist, aims to enhance brain energy metabolism and neuroplasticity, presenting a differentiated mechanism for treating depression. The treatment exhibited a favorable safety profile, with no serious adverse events reported. The U.S. FDA has granted elunetirom Fast Track designation, expediting its development process. Autobahn plans to present full trial results at a medical conference in 2026 and is also exploring elunetirom's efficacy in major depressive disorder through an ongoing Phase 2 trial, with results expected later in 2026. This research addresses a significant unmet need in bipolar depression, which affects approximately 7 million adults in the U.S.
Advertisement
In-Article Ad
The positive results from the elunetirom trial could provide a new treatment option for the millions suffering from bipolar depression, potentially improving their quality of life.
Advertisement
In-Article Ad
Reader Poll
What do you think about the potential of elunetirom as a treatment for bipolar depression?
Connecting to poll...
Read the original article
Visit the source for the complete story.